Clinical Trial Update: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating alisertib with or without rituximab in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Alisertib (alisertib)
• Rituximab (rituximab)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-06-06